GSK0660 is a selective PPAR antagonist. GSK0660 differentially regulated 273 transcripts in TNF-treated cells compared to TNF alone. A pathway analysis revealed the enrichment of cytokine-cytokine receptor signaling. In particular, GSK0660 blocks the TNF-induced upregulation of CCL8, a chemokine involved in leukocyte recruitment. GSK0660 blocks the effect of TNF on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CCL17, and CXCL10 and it may therefore block TNF-induced retinal leukostasis.
For research use only. We do not sell to patients.